Get started
Syros Pharmaceuticals, Inc.Syros Pharmaceuticals, Inc.Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SYRS chart


Full chart

SYRS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.61 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.0312 USD
Net income (FY)
‪−164.57 M‬ USD
Revenue (FY)
‪9.94 M‬ USD
Shares float
‪17.43 M‬
Beta (1Y)
2.55

Employees


Employees (FY)
68
Change (1Y)
−49 −41.88%
Revenue / Employee (1Y)
‪146.12 K‬ USD
Net income / Employee (1Y)
‪−2.42 M‬ USD

About Syros Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gerald E. Quirk
Website
syros.com
Headquarters
Cambridge
Founded
2011
FIGI
BBG004FFTL76
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SYRS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SYRS is 0.2083 USD — it has decreased by −3.20% in the past 24 hours. Watch Syros Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Syros Pharmaceuticals, Inc. stocks are traded under the ticker SYRS.
SYRS stock has fallen by −0.48% compared to the previous week, the month change is a −16.70% fall, over the last year Syros Pharmaceuticals, Inc. has showed a −97.12% decrease.
We've gathered analysts' opinions on Syros Pharmaceuticals, Inc. future price: according to them, SYRS price has a max estimate of 20.00 USD and a min estimate of 1.00 USD. Watch SYRS chart and read a more detailed Syros Pharmaceuticals, Inc. stock forecast: see what analysts think of Syros Pharmaceuticals, Inc. and suggest that you do with its stocks.
SYRS reached its all-time high on Aug 7, 2017 with the price of 243.7500 USD, and its all-time low was 0.1830 USD and was reached on Nov 18, 2024. View more price dynamics on SYRS chart.
See other stocks reaching their highest and lowest prices.
SYRS stock is 6.95% volatile and has beta coefficient of 2.55. Track Syros Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Syros Pharmaceuticals, Inc. there?
Today Syros Pharmaceuticals, Inc. has the market capitalization of ‪5.61 M‬, it has decreased by −2.92% over the last week.
Yes, you can track Syros Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Syros Pharmaceuticals, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
SYRS earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.68 USD resulting in a 76.34% surprise. The estimated earnings for the next quarter are −0.72 USD per share. See more details about Syros Pharmaceuticals, Inc. earnings.
Syros Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪360.00 K‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
SYRS net income for the last quarter is ‪−6.40 M‬ USD, while the quarter before that showed ‪−23.33 M‬ USD of net income which accounts for 72.58% change. Track more Syros Pharmaceuticals, Inc. financial stats to get the full picture.
No, SYRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 68.00 employees. See our rating of the largest employees — is Syros Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Syros Pharmaceuticals, Inc. EBITDA is ‪−110.25 M‬ USD, and current EBITDA margin is ‪−1.25 K‬%. See more stats in Syros Pharmaceuticals, Inc. financial statements.
Like other stocks, SYRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Syros Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Syros Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Syros Pharmaceuticals, Inc. stock shows the sell signal. See more of Syros Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.